MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with B

Bictegravir + Emtricitabine + Tenofovir alafenamide

Bictegravir 30mg / Emtricitabine 120mg / Tenofovir alafenamide 15mg tablets

No stability information

Stability notes for Bictegravir 30mg / Emtricitabine 120mg / Tenofovir alafenamide 15mg tablets

There are no stability notes for this medicine.

Supplier

Biktarvy 30mg/120mg/15mg tablets (Gilead Sciences Ltd)

Bictegravir 50mg / Emtricitabine 200mg / Tenofovir alafenamide 25mg tablets

No stability information

Stability notes for Bictegravir 50mg / Emtricitabine 200mg / Tenofovir alafenamide 25mg tablets

There are no stability notes for this medicine.

Supplier

Biktarvy 50mg/200mg/25mg tablets (Gilead Sciences Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.